Literature DB >> 2553158

Inhibition of chemotaxis Ng-monomethyl-L-arginine: a role for cyclic GMP.

S S Kaplan1, T Billiar, R D Curran, U E Zdziarski, R L Simmons, R E Basford.   

Abstract

The metabolism of L-arginine to nitric oxide (NO) has been shown to be important for the effector functions of many cell types, including polymorphonuclear (PMN) leukocytes. Its effect appears to be mediated at least in part by NO stimulation of soluble guanylate cyclase. We evaluated the role of this pathway in two PMN effector functions: cell movement and microbial killing, using the competitive inhibitor of L-arginine conversion to NO, NG-monomethyl-L-arginine (NMA). We also evaluated the effect of additional L-arginine and dibutyryl cyclic guanosine monophosphate (cGMP) on any NMA-associated changes. Human peripheral blood neutrophils were used and the cells were incubated with and without NMA. Chemotaxis was evaluated using a 48-well micro-Boyden chamber. Microbial killing was evaluated using S aureus strains D2C and 502A. These studies demonstrated that chemotaxis to formyl-methionyl-leucyl-phenylalanine was markedly inhibited in NMA-treated cells. This inhibition could be overcome if L-arginine or dibutyryl cGMP were added with the NMA. In contrast, microbial killing of S aureus was unaffected by NMA. These observations support the hypothesis that the L-arginine metabolism to NO and its effect on the cGMP level may be important for the dynamic changes required for neutrophil chemotaxis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553158

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Multiple cytokines are required to induce hepatocyte nitric oxide production and inhibit total protein synthesis.

Authors:  R D Curran; T R Billiar; D J Stuehr; J B Ochoa; B G Harbrecht; S G Flint; R L Simmons
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

2.  Differential inhibition and potentiation of chemoattractant-induced superoxide formation in human neutrophils by the cell-permeant analogue of cyclic GMP, N2,2'-O-dibutyryl guanosine 3':5'-cyclic monophosphate.

Authors:  J Ervens; G Schultz; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-04       Impact factor: 3.000

3.  Nitrogen oxide levels in patients after trauma and during sepsis.

Authors:  J B Ochoa; A O Udekwu; T R Billiar; R D Curran; F B Cerra; R L Simmons; A B Peitzman
Journal:  Ann Surg       Date:  1991-11       Impact factor: 12.969

4.  Proinflammatory and antimicrobial nitric oxide in gingival fluid of diabetic patients with periodontal disease.

Authors:  Uros Skaleric; Boris Gaspirc; Nancy McCartney-Francis; Andrej Masera; Sharon M Wahl
Journal:  Infect Immun       Date:  2006-10-02       Impact factor: 3.441

5.  Interaction of nitric oxide synthase inhibitors and their D-enantiomers with rat neutrophil luminol dependent chemiluminescence response.

Authors:  M Dikshit; S S Chari; P Seth; R Kumari
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

Review 6.  Inducible nitric oxide synthase in inflammation.

Authors:  V Cattell; A Jansen
Journal:  Histochem J       Date:  1995-10

7.  Nitric oxide-generating system as an autocrine mechanism in human polymorphonuclear leucocytes.

Authors:  A Riesco; C Caramelo; G Blum; M Montón; M J Gallego; S Casado; A López Farré
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

8.  Inducible nitric oxide expression correlates with the level of inflammation in periapical cysts.

Authors:  Mariza Akemi Matsumoto; Daniel Araki Ribeiro
Journal:  Eur J Dent       Date:  2007-10

9.  Modulation of neutrophil migration by captopril.

Authors:  J G Elferink; B M de Koster
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

10.  Nitric oxide regulates neutrophil migration through microparticle formation.

Authors:  Sarah Nolan; Rachel Dixon; Keith Norman; Paul Hellewell; Victoria Ridger
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.